Synthesized Anti-HER2 Trastuzumab-MCCDM1 Conjugate: An Evaluation of Efficacy and Cytotoxicity

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

Shafiee Soodabeh; MIRZAEI ROYA; Salehi Maliheh; JALILI NEDA; TAHERI AMIR; FARAHMAND LEILA

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Iranian Journal of Immunology Year:2023 | Volume:20 | Issue:3 Page(s): 303-315

Download Full-Text

View:

Download:

Cites:

Information Journal Paper

Title

Synthesized Anti-HER2 Trastuzumab-MCCDM1 Conjugate: An Evaluation of Efficacy and Cytotoxicity

Author(s)

Keywords

Breast Neoplasms

Immunoconjugates

Therapeutic Index

Trastuzumab

Abstract

Background: Trastuzumab is a humanized monoclonal antibody that targets site-specifically human epidermal growth factor-2 receptor (HER2) cell surface antigen overexpressed in approximately 20% of human breast carcinomas. Despite its positive therapeutic outcomes, a large proportion of individuals are unresponsive to the treatment with the Trastuzumab or develop resistance to it. Objective: To evaluate a chemically synthesized Trastuzumabbased antibody-drug conjugate (ADC) to improve the Trastuzumab Therapeutic Index. Methods: The current study explored the physiochemical characteristics of the Trastuzumab conjugated to a cytotoxic chemotherapy agent DM1 via Succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker, created in our earlier study, using SDS-PAGE, UV/ VIS, and RP-HPLC analyses. The antitumor effects of the ADCs were analyzed using MDA-MB-231 (HER2-negative) and SK-BR-3 (HER2-positive) cell lines utilizing in vitro cytotoxicity, viability, and binding assays. Three different formats of a HER2-targeting agent: Trastuzumab, synthesized Trastuzumab-MCC-DM1, and commercially available drug T-DM1 (Kadcyla®, ) were compared. Results: UV-VIS spectroscopic analysis showed that the Trastuzumab-MCC-DM1 conjugates, on average, entailed 2. 9 DM1 payloads per Trastuzumab. A free drug level of 2. 5% was determined by RP-HPLC. The conjugate appeared as two bands on a reducing SDS-PAGE gel. MTT viability assay showed that conjugating Trastuzumab with DM1 significantly improved the antiproliferative effects of this antibody in vitro. Importantly, the evaluations using LDH release and cell apoptosis assays confirmed that Trastuzumab maintains its ability to induce cell death response while conjugating with the DM1. The binding efficiency of Trastuzumab-MCC-DM1 was comparable to that of the naked Trastuzumab. Conclusion: Trastuzumab-MCC-DM1 was found effective against HER2+ tumors. The potency of this synthesized conjugate brings it closer to the commercially available T-DM1.

Cites

No record.

References

No record.

Cite

APA: Copy

Shafiee, Soodabeh, MIRZAEI, ROYA, Salehi, Maliheh, JALILI, NEDA, TAHERI, AMIR, & FARAHMAND, LEILA. (2023). Synthesized Anti-HER2 Trastuzumab-MCCDM1 Conjugate: An Evaluation of Efficacy and Cytotoxicity. IRANIAN JOURNAL OF IMMUNOLOGY (IJI), 20(3), 303-315. SID. https://sid.ir/paper/1145613/en

Vancouver: Copy

Shafiee Soodabeh, MIRZAEI ROYA, Salehi Maliheh, JALILI NEDA, TAHERI AMIR, FARAHMAND LEILA. Synthesized Anti-HER2 Trastuzumab-MCCDM1 Conjugate: An Evaluation of Efficacy and Cytotoxicity. IRANIAN JOURNAL OF IMMUNOLOGY (IJI)[Internet]. 2023;20(3):303-315. Available from: https://sid.ir/paper/1145613/en

IEEE: Copy

Soodabeh Shafiee, ROYA MIRZAEI, Maliheh Salehi, NEDA JALILI, AMIR TAHERI, and LEILA FARAHMAND, “Synthesized Anti-HER2 Trastuzumab-MCCDM1 Conjugate: An Evaluation of Efficacy and Cytotoxicity,” IRANIAN JOURNAL OF IMMUNOLOGY (IJI), vol. 20, no. 3, pp. 303–315, 2023, [Online]. Available: https://sid.ir/paper/1145613/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops